Pacira BioSciences, Inc. (PCRX) financial statements (2020 and earlier)

Company profile

Business Address 5 SYLVAN WAY
PARSIPPANY, NJ 07054
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
12/31/2013
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments29238331117315915772
Cash and cash equivalents781335436573813
Short-term investments21425125713710211960
Receivables48383230262215
Inventory, net of allowances, customer advances and progress billings58494131622916
Inventory58494131622916
Other undisclosed current assets11879664
Total current assets:409478391243253214107
Noncurrent Assets
Property, plant and equipment105109107101906148
Long-term investments and receivables652660 1324 
Long-term investments652660 1324 
Intangible assets, net (including goodwill)204625547312411
Goodwill100625547312410
Intangible assets, net (excluding goodwill)104   001
Other noncurrent assets 111233
Other undisclosed noncurrent assets491414    
Total noncurrent assets:42321123714813711263
TOTAL ASSETS:831689628391390326170
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities85605644444426
Accounts payable1314158973
Accrued liabilities70464137352818
Employee-related liabilities     95
Taxes payable10000  
Debt 00  120120
Asset retirement obligation1      
Deferred revenue and credits01111
Other undisclosed current liabilities23   106(26)(26)
Total current liabilities:108615645152140122
Noncurrent Liabilities
Long-term debt and lease obligation306291276109   
Long-term debt, excluding current maturities306291276109   
Liabilities, other than long-term debt217161920199
Deferred revenue and credits 78146
Other liabilities21716111153
Other undisclosed noncurrent liabilities61    (5)(2)
Total noncurrent liabilities:36830729312820157
Total liabilities:476368349172171155129
Stockholders' equity
Stockholders' equity attributable to parent35532127921921817141
Common stock0000000
Additional paid in capital754710669565527481338
Accumulated other comprehensive income (loss)0(0)(0)(0)(0)(0)0
Accumulated deficit(399)(388)(389)(346)(308)(310)(296)
Total stockholders' equity:35532127921921817141
TOTAL LIABILITIES AND EQUITY:831689628391390326170

Income statement (P&L) ($ in millions)

12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
12/31/2013
Revenues42133728727624919886
Revenue, net33428627324819685
Cost of revenue(107)(87)(88)(110)(72)(77)(55)
Cost of goods and services sold      (55)
Gross profit:31425019916617712031
Operating expenses(411)(321)(312)(308)(240)(203)(139)
Other undisclosed operating income1078788110727755
Operating income (loss):1016(25)(32)9(5)(53)
Nonoperating expense(21)(16)(18)(6)(7)(8)(11)
Investment income, nonoperating7641100
Other nonoperating income (expense)(5)(1)0(0)(0)(0)(0)
Interest and debt expense(24)(22)(4)(7)(0)(8)(11)
Income (loss) from continuing operations before equity method investments, income taxes:(34)(22)(46)(45)2(22)(75)
Other undisclosed income from continuing operations before income taxes2422470811
Income (loss) from continuing operations before income taxes:(11)(0)(42)(38)2(14)(64)
Income tax expense (benefit)(0)(0)(0)(0)(0)(0)0
Net income (loss) available to common stockholders, diluted:(11)(0)(43)(38)2(14)(64)

Comprehensive Income ($ in millions)

12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
12/31/2013
Net income (loss):(11)(0)(43)(38)2(14)(64)
Comprehensive income (loss):(11)(0)(43)(38)2(14)(64)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent10(0)00(0)(0)
Comprehensive income (loss), net of tax, attributable to parent:(10)(0)(43)(38)2(14)(64)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: